Biomarkers to predict and evaluate the reactivity of subjects with endometrial cancer to compounds with lenvatinib

摘要

A method for predicting the response of a human subject suffering from, is presumed to be suffering from or at risk of developing endometrial cancer, to a treatment comprising lenvatinib or a pharmaceutically acceptable salt thereof, the method comprises: testing a biological sample obtained from the human subject and determine that the concentration of the Angiopoietin 2 (Ang2) protein in the biological sample is low, compared to a control; and identifying that the human subject that has a low concentration of the Ang2 protein in the biological sample is likely to respond to treatment comprising lenvatinib or a pharmaceutically acceptable salt thereof.